Literature DB >> 22367999

Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.

Anil Kachroo1, Michael A Schwarzschild.   

Abstract

To investigate the putative interaction between chronic exposure to adenosine receptor antagonist caffeine and genetic influences on Parkinson's disease (PD), we determined whether deletion of the adenosine A(2A) receptor in knockout (KO) mice protects against dopaminergic neuron degeneration induced by a mutant human α-synuclein (hm(2)-αSYN) transgene containing both A53T and A30P. The A(2A) KO completely prevented loss of dopamine and dopaminergic neurons caused by the mutant α-synuclein transgene without altering levels of its expression. The adenosine A(2A) receptor appears required for neurotoxicity in a mutant α-synuclein model of PD. Together with prior studies the present findings indirectly support the neuroprotective potential of caffeine and more specific A(2A) antagonists.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367999      PMCID: PMC3292742          DOI: 10.1002/ana.22630

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

1.  A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice.

Authors:  J F Chen; Z Huang; J Ma; J Zhu; R Moratalla; D Standaert; M A Moskowitz; J S Fink; M A Schwarzschild
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

2.  Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.

Authors:  Ken Ikeda; Masako Kurokawa; Shiro Aoyama; Yoshihisa Kuwana
Journal:  J Neurochem       Date:  2002-01       Impact factor: 5.372

Review 3.  Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs.

Authors:  Bertil B Fredholm; Jiang-Fan Chen; Susan A Masino; Jean-Marie Vaugeois
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

Review 4.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

5.  Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.

Authors:  Eric K Richfield; Mona J Thiruchelvam; Deborah A Cory-Slechta; Charles Wuertzer; Raul R Gainetdinov; Marc G Caron; Donato A Di Monte; Howard J Federoff
Journal:  Exp Neurol       Date:  2002-05       Impact factor: 5.330

6.  Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

Authors:  J F Chen; K Xu; J P Petzer; R Staal; Y H Xu; M Beilstein; P K Sonsalla; K Castagnoli; N Castagnoli; M A Schwarzschild
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

7.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

Authors:  A Ascherio; S M Zhang; M A Hernán; I Kawachi; G A Colditz; F E Speizer; W C Willett
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

Review 8.  Preclinical jockeying on the translational track of adenosine A2A receptors.

Authors:  Melita T Barkhoudarian; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2011-01-04       Impact factor: 5.330

9.  Proteasome dysfunction in aged human alpha-synuclein transgenic mice.

Authors:  Li Chen; Mona J Thiruchelvam; Kiran Madura; Eric K Richfield
Journal:  Neurobiol Dis       Date:  2006-05-19       Impact factor: 5.996

Review 10.  Pathophysiological roles for purines: adenosine, caffeine and urate.

Authors:  Micaela Morelli; Anna R Carta; Anil Kachroo; Michael A Schwarzschild
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

View more
  34 in total

1.  Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease.

Authors:  Anil Kachroo; Michael A Schwarzschild
Journal:  Brain Res       Date:  2014-03-26       Impact factor: 3.252

2.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

3.  A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.

Authors:  C Laurent; S Burnouf; B Ferry; V L Batalha; J E Coelho; Y Baqi; E Malik; E Mariciniak; S Parrot; A Van der Jeugd; E Faivre; V Flaten; C Ledent; R D'Hooge; N Sergeant; M Hamdane; S Humez; C E Müller; L V Lopes; L Buée; D Blum
Journal:  Mol Psychiatry       Date:  2014-12-02       Impact factor: 15.992

4.  The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival.

Authors:  Xiqun Chen; Hongxiang Chen; Waijiao Cai; Michael Maguire; Bailiu Ya; Fuxing Zuo; Robert Logan; Hui Li; Katey Robinson; Charles R Vanderburg; Yang Yu; Yinsheng Wang; David E Fisher; Michael A Schwarzschild
Journal:  Ann Neurol       Date:  2017-01-23       Impact factor: 10.422

5.  Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound.

Authors:  Kristiana Xhima; Fadl Nabbouh; Kullervo Hynynen; Isabelle Aubert; Anurag Tandon
Journal:  Mov Disord       Date:  2018-09-28       Impact factor: 10.338

Review 6.  Coffee, Genetic Variants, and Parkinson's Disease: Gene-Environment Interactions.

Authors:  Naomi Yamada-Fowler; Peter Söderkvist
Journal:  J Caffeine Res       Date:  2015-03-01

7.  α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B.

Authors:  Diana G Ferreira; Mariana Temido-Ferreira; Hugo Vicente Miranda; Vânia L Batalha; Joana E Coelho; Éva M Szegö; Inês Marques-Morgado; Sandra H Vaz; Jeong Seop Rhee; Matthias Schmitz; Inga Zerr; Luísa V Lopes; Tiago F Outeiro
Journal:  Nat Neurosci       Date:  2017-09-25       Impact factor: 24.884

Review 8.  Animal models of Parkinson's disease: a gateway to therapeutics?

Authors:  Weidong Le; Pavani Sayana; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 9.  Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.

Authors:  Michail Sitkovsky; Akio Ohta
Journal:  J Mol Med (Berl)       Date:  2013-01-20       Impact factor: 4.599

10.  Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.

Authors:  David K Simon; Cai Wu; Barbara C Tilley; Anne-Marie Wills; Michael J Aminoff; Jacquelyn Bainbridge; Robert A Hauser; Jay S Schneider; Saloni Sharma; Carlos Singer; Caroline M Tanner; Daniel Truong; Pei Shieen Wong
Journal:  Clin Neuropharmacol       Date:  2015 Sep-Oct       Impact factor: 1.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.